Newsroom

latest news from ose
and across our portfolio

Featured News

Oxford Spinout Oxford Semantic Technologies acquired by Samsung Electronics
Oxford Spinout Oxford Semantic Technologies acquired by Samsung ElectronicsArticle links to www.oxionics.com
Oxford Ionics breaks global quantum performance records
Oxford Ionics breaks global quantum performance records
Times Commentary: Science innovation must be at the heart of government action
Times Commentary: Science innovation must be at the heart of government actionArticle links to www.beacontx.com
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene TherapiesArticle links to www.prnewswire.com
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptography
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptographyArticle links to www.globenewswire.com
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raises
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raisesArticle links to www.businesswire.com
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group

All News

Portfolio NewsScenic BiotechScenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882Portfolio NewsScenic BiotechScenic Biotech enters cooperative research and development agreement with the National Institutes of Health for genetic modifier-based treatment approach for Niemann-Pick Type C DiseasePortfolio NewsScenic BiotechScenic Biotech strengthens drug discovery expertise in management team with the addition of Kristof Van EmelenPortfolio NewsScenic BiotechScenic Biotech appoints Jens Würthner as Chief Medical OfficerPortfolio NewsScenic BiotechScenic Biotech and the Barth Syndrome Foundation announce partnership to explore genetic modifiers to find tailored treatment for complex rare diseasePortfolio NewsScenic BiotechScenic Biotech announces $31 million financing to progress pipeline of genetic modifiers in cancer and rare diseasesPortfolio NewsScenic BiotechScenic Biotech appoints Dr. Philippe Dro as Independent ChairmanPortfolio NewsScenic BiotechScenic Biotech enters into genetic modifier collaboration with Genentech